Interleukin-21 is a growth and survival factor for human myeloma cells

Blood

Volumn 99, Issue 10, 2002, Pages 3756-3762

  Brenne, Anne Tove ^a   Ro, Torstein Baade ^a   Waage, Anders ^a   Sundan, Anders ^a   Borset, Magne ^a   Hjorth Hansen, Henrik ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 21; INTERLEUKIN DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; DNA SYNTHESIS; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0037093258     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3756     Document Type: Article

References (39)

1. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials: Myeloma Trialists' Collaborative Group
2. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study: Nordic Myeloma Study Group
3. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma
4. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
5. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
6. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor
7. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line
8. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines
9. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop
10. Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells
11. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines
12. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells
13. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma
14. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6
15. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function
16. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain
17. Cutting edge: The common gamma-chain is an indispensable subunit of the IL-21 receptor complex
18. Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2
19. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells
20. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: A reappraisal 18 years after
21. Detection of Epstein-Barr virus, but not human herpesvirus 8, DNA in cervical secretions from Swedish women by real-time polymerase chain reaction
22. A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
23. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation
24. Hepatocyte growth factor and its receptor c-met in multiple myeloma
25. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
26. Cytobiological studies in multiple myeloma
27. Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11
28. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
29. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
30. The role of the two TNF receptors in proliferation, NF-kappa B activation and discrimination between TNF and LT alpha signalling in the human myeloma cell line OH-2
31. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
32. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation
33. Effects of B cell stimulatory factor-1/interleukin 4 on hematopoietic progenitor cells
34. Stimulation of B-cell progenitors by cloned murine interleukin-7
35. Update of gp130 cytokines in multiple myeloma
36. The molecular basis of X-linked severe combined immunodeficiency: The role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c
37. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
38. Longterm oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma
39. High levels of soluble syndecan-1, in myeloma-derived bone marrow: Modulation of hepatocyte growth factor activity